Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 15 of 30
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
NCT03539900
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
NCT04057807
Optimizing Electronic Alerts for Acute Kidney Injury
NCT02753751
Home vs. Office Foley Catheter Removal in Women With Voiding Difficulty Following Pelvic Reconstructive Surgery
NCT03373773
Effect of Physician Race and Gender on Simulated Patients' Ratings
NCT04190901
Investigation of Cocaine Addiction Using mGluR5 PET and fMRI
NCT03471182
Electronic Cigarette Use in Young Adult Men and Women
NCT03089541
Ketamine in Borderline Personality Disorder
NCT03395314
Mavoglurant in Alcohol Drinking
NCT03327792
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
NCT03526185
Comparison of Intravascular Uptake and Pain Perception During Epidural Injection Using 22 Gauge vs 25 Gauge Needle
NCT04350307
Hand Grip Strength as a Marker of Frailty in Surgical Patients
NCT02966470
Post-Market Surveillance With a Novel mHealth Platform
NCT03436082
Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention
NCT03373240
Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose
NCT03469492
Does Mindfulness Enhance BMI in Obese Adolescents Enrolled in the Bright Bodies Weight Management Program?
NCT03611660
Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks
NCT03293290
Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations
NCT03191084
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
NCT04327934
Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes
NCT03356457
Imaging the Neurochemistry of Drug Addiction With PET
NCT02817698
Glucocorticoid Antagonist Treatment for Tobacco Use Disorder
NCT03248713
Pregnancy, Mindfulness, and Massage
NCT03276208
Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy
NCT03234491
Brief Interventions With Text Messaging to Reduce Adolescent Alcohol and Marijuana Use
NCT03401333
Psilocybin for the Treatment of Migraine Headache
NCT03341689
Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients
NCT03353792
The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
NCT03535883
Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults
NCT03751020
Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents (smokeScreen)
NCT03722888
Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)
NCT03183388
Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin
NCT03400501
Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures
NCT02908516
Development of Reward Processing in Prenatally Exposed Adolescents and Young Adults
NCT03268759
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
NCT03063606
Patient Driven Recovery With Nalmefene and Coaching
NCT03279562
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
NCT03047005
Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)
NCT03174808
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
NCT03103750
Toradol to Reduce Ureteroscopic Symptoms Trial
NCT03111381
Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder
NCT03206463
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
NCT03262779
STAMP: Sharing and Talking About My Preferences
NCT03137459
A Sunscreen Based on Bioadhesive Nanoparticles
NCT02668536
Mindfulness Based Stress Reduction for Metabolic Syndrome
NCT03296514
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
NCT03027960
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
NCT03099265
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
NCT02994251
Project SMART Automated Pillbox Study
NCT04418076
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
NCT03132571
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.